Table 2.
First Author, Year [ref] | Experimental Design and Treatments | Results |
---|---|---|
In vitro study | ||
Ha, 2012 [36] | BV-2 cells were cultured and activated with LPS (1 mg/mL) for 12 h. LPS was removed from the cells and indicated 6-shogaol (1, 5, 10 μM) was added. NMMA, an inhibitor of iNOS enzyme activity, was used as a positive control | Compared to control group, 6-shogaol groups: |
↓ iNOS expression and release of NO | ||
↓ microglial activation | ||
Hosseinzadeh, 2017 [37] | C28I2 human chondrocytes pretreated with GE (5, 25 μg/mL) for 24 h, followed by incubation with IL-1β (10 ng/mL) for 24 h | Compared to vehicle group, GE groups: |
↑ anti-oxidant enzyme gene expression | ||
↓ reactive oxygen species | ||
↓ lipid peroxidation | ||
↓ Bax/Bcl ratio, inhibiting apoptosis | ||
↓ caspase-3 activity | ||
Animal studies | ||
Montserrat-de la Paz, 2018 [38] | Intermittent cold stress (ICS)-induced FM model | Compared to control group, GR groups: |
Female C57BL/6 J mice (n = 48, 5-week-old) | ↓ mechanical and thermal allodynia | |
↓ mechanical hyperalgesia | ||
Treatments: healthy control, ICS group, ICS + APAP (40 mg/kg/day), ICS + GR (0.5%, 1%), and ICS + GR (0.5%) + APAP (40 mg/kg/day) supplemented with standard diet for 8 weeks | ↑ improved behavioral changes related to cognitive disturbances associated with pain, anxiety, and depression ↓ proinflammatory mediators such as NO, PGE2, TXB2, IL-1β in LPS-stimulated macrophages |
|
↑ synergism with APAP leading to further reduction in FM-like symptoms | ||
Fajrin, 2019 [39] | Complete Freud’s Adjuvant (CFA)-induced FM-like model | Compared to control group, RGO groups: |
Male mice (n = 48, 8-week-old) | ↓ hyperalgesia in a dose-dependent manner | |
Treatments: sham, negative control, RGO doses at 100, 200, 400 and 600 mg/kg orally 1x/day for 7 days | ↑ thermal response threshold | |
Abolaji, 2017 [40] | Chlorpyrifos (CPF)-induced FM-like model | Compared to the control group, 6-GRF groups: |
Female Wistar rats (n = 70, 100–125 g) | ↓ H2O2 and MDA levels | |
↑ catalase, SOD, GPX activity | ||
Treatments: control with corn oil only (2 mL/kg BW), 6-GRF (100 mg/kg BW), CPF dissolved in corn oil (5 mg/kg BW), CPF (5 mg/kg BW) and 6-GRF (50 mg/kg BW) concomitantly, CPF (5 mg/kg BW) and 6-GRF (100 mg/kg BW) concomitantly 1x/day for 35 days after CPF toxicity | ↓ NO, MPO, TNF-α | |
↓ caspase-3 | ||
Zhang, 2016 [41] | DSS-induced chronic colitis model | Compared to control group, GDNP group: |
Female FVB/NJ mice (n = 7, 6–8-week-old) | ↑ healing in wounded intestinal epithelial monolayers | |
↑ proliferation of IECs | ||
Groups including control with normal feeding and GDNPs 2 (300 μL of 1 mg/mL solution) by oral gavage 1x/day for 18 weeks | ↓ TNF-α, IL-6, IL-1β, MPO | |
↑ IL-10, IL-22 |
Abbreviations: APAP, paracetamol; BW, birth weight; CFA, complete Freud’s Adjuvant; CPF, chlorpyrifos; DSS, dextran sodium sulfate; FM, fibromyalgia; ICS, intermittent cold stress; IL-1β, interleukin-1β; GE, ginger extract; GPX, glutathione peroxidase, GR, ginger rhizome; GRF, gingerol-rich fraction; H2O2, hydrogen peroxide; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MDA, malondialdehyde; MPO, myeloperoxidase; NO, nitric oxide; PGE2, prostaglandin E2; RGO, red ginger oil; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α; TXB2, thromboxane B2; ↑ increase; ↓ decrease; ↔ no difference.